Masanori Noguchi

Summary

Affiliation: Kurume University School of Medicine
Country: Japan

Publications

  1. doi request reprint Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination
    Kanako Iseki
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Fukuoka, Japan
    Cancer Sci 101:2110-4. 2010
  2. pmc A case of primary mucosa-associated lymphoid tissue lymphoma of the prostate
    Noriko Koga
    Departments of Urology
    Rare Tumors 1:e55. 2009
  3. pmc A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
    Masanori Noguchi
    Clinical Research Division of the Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    BMC Cancer 13:613. 2013
  4. doi request reprint Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Cancer Immunol Immunother 62:919-29. 2013
  5. doi request reprint Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy
    Masanori Noguchi
    Division of Clinical Research of the Research Center for Innovative Cancer Therapy, Kurume University School ofMedicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Prostate 72:834-45. 2012
  6. ncbi request reprint Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Int J Urol 11:103-9. 2004
  7. ncbi request reprint Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Oncol Res 16:341-9. 2007
  8. ncbi request reprint Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Prostate 67:933-42. 2007
  9. ncbi request reprint Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, ururume 830 0011, Japan
    Cancer Sci 95:77-84. 2004
  10. ncbi request reprint Transurethral electrovaporization for giant prostatic hyperplasia: report of a case
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Kurume Med J 50:151-3. 2003

Detail Information

Publications77

  1. doi request reprint Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination
    Kanako Iseki
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Fukuoka, Japan
    Cancer Sci 101:2110-4. 2010
    ....
  2. pmc A case of primary mucosa-associated lymphoid tissue lymphoma of the prostate
    Noriko Koga
    Departments of Urology
    Rare Tumors 1:e55. 2009
    ..The patient received external beam radiation therapy to the prostate with a total dose of 3600cGy in 22 fractions, and became free of disease within the following 15 months...
  3. pmc A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
    Masanori Noguchi
    Clinical Research Division of the Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    BMC Cancer 13:613. 2013
    ..The purpose of this study was to assess prospectively the PSA kinetics and immune responses, as well as the efficacy, safety, and biomarkers of personalized peptide vaccination (PPV) in progressive CRPC...
  4. doi request reprint Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Cancer Immunol Immunother 62:919-29. 2013
    ..In this review, we discuss our recent results of preclinical and clinical studies of PPV for various types of advanced cancer...
  5. doi request reprint Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy
    Masanori Noguchi
    Division of Clinical Research of the Research Center for Innovative Cancer Therapy, Kurume University School ofMedicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Prostate 72:834-45. 2012
    ..To explore cancer vaccine as a new treatment modality, we conducted a phase II study of personalized peptide vaccine (PPV) for DBC-resistant CRPC patients...
  6. ncbi request reprint Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Int J Urol 11:103-9. 2004
    ....
  7. ncbi request reprint Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Oncol Res 16:341-9. 2007
    ..0347, odds ratio 2.569) were independent predictors of disease death. These encouraging results show the need for further evaluation of the combination of personalized peptide vaccination and low dose of EMP for metastatic HRPC patients...
  8. ncbi request reprint Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Prostate 67:933-42. 2007
    ..The purpose of this study was to determine the safety and immune responses of pre-operative personalized peptide vaccine for patients with localized prostate cancer...
  9. ncbi request reprint Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, ururume 830 0011, Japan
    Cancer Sci 95:77-84. 2004
    ..We consider that the increase in cellular and humoral immune responses, and decrease in PSA level in some patients justify further development of peptide vaccination for metastatic HRPC patients...
  10. ncbi request reprint Transurethral electrovaporization for giant prostatic hyperplasia: report of a case
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Kurume Med J 50:151-3. 2003
    ..We report a case undergoing removal over 200 g of prostatic adenoma by three transurethral electrovaporization (TVP) sessions and discuss its feasibility in clinical use...
  11. ncbi request reprint Early catheter removal 3 days after radical retropubic prostatectomy
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Int J Urol 11:983-8. 2004
    ..We investigated the feasibility and safety of the early removal of urethral catheters 3 days after radical retropubic prostatectomy...
  12. ncbi request reprint Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Asahi machi, Kurume, Japan
    Prostate 60:32-45. 2004
    ..Additive antitumor effects could be achieved by combination of immunotherapy and cytotoxic agents with no or minimum suppression...
  13. ncbi request reprint Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients
    Masanori Noguchi
    Department of Urology, Kurume University, Kurume, Japan
    Prostate 63:1-12. 2005
    ..The safety, toxicity, and immunological response of individualized peptide vaccination or human leukocyte antigen (HLA)-A24+ hormone refractory prostate cancer (HRPC) patients in combination with a low dose of estramustine were evaluated...
  14. ncbi request reprint A questionnaire survey of patient preparation and techniques for prostate biopsy among urologists in the Kyushu and Okinawa regions of Japan
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, 67 Asahi Machi, Kurume, 830 0011, Japan
    Int J Clin Oncol 11:390-5. 2006
    ..We surveyed urologists in the Kyushu and Okinawa regions of Japan regarding their standard approach to patient preparation and their prostate biopsy technique...
  15. ncbi request reprint Evaluation of a prostate biopsy strategy for cancer detection using a computer simulation system with virtual needle biopsy for three-dimensional prostate models
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Int J Urol 13:1296-303. 2006
    ..We evaluated a prostate biopsy strategy for cancer detection using a computer simulation system with virtual needle biopsy for three-dimensional (3D) prostate models...
  16. ncbi request reprint Suspension technique improves rapid recovery of urinary continence following radical retropubic prostatectomy
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume 830 0011, Japan
    Kurume Med J 51:245-51. 2004
    ..001] and 67% [p<0.01]) of the control group. The suspension technique appears to have an advantage in immediate recovery of urinary continence following radical retropubic prostatectomy...
  17. ncbi request reprint Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-ranging study
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Asian J Androl 10:651-8. 2008
    ..To conduct a double-blind, placebo-controlled randomized and dose-ranging study to evaluate the safety and efficacy of the extract of Ganoderma lucidum (G. lucidum) in men with lower urinary tract symptoms (LUTS)...
  18. ncbi request reprint Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830 0011, Japan
    Asian J Androl 10:777-85. 2008
    ....
  19. ncbi request reprint Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination
    Masanori Noguchi
    Division of Clinical Research, Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
    Cancer Biol Ther 10:1266-79. 2010
    ..000282 and P = 0.00045). In contrast, CTL responses were not statistically different between the two groups. Both lymphocyte numbers and IgG response were thus suggested to be biomarkers of cancer vaccine for advanced cancer patients...
  20. doi request reprint A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Prostate 71:470-9. 2011
    ..To evaluate the safety, tolerability, immune response, and antitumor activity of a combination of personalized peptide vaccination (PPV) and estramustine phosphate (EMP) in patients with castration-resistant prostate cancer (CRPC)...
  21. ncbi request reprint No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Oncol Rep 9:1075-80. 2002
    ..03-3.56). Downstaging to pT0 occurs after duration of NHT of longer than 3 months. Further investigation of the optimal duration of NHT for downstaging and for improving patients' survival should be accomplished in randomized trials...
  22. doi request reprint A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Cancer Immunol Immunother 59:1001-9. 2010
    ..PPV plus low-dose EMP was associated with an improvement in PSA-based PFS as compared to the standard-dose EMP alone...
  23. pmc Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer
    M Noguchi
    Department of Urology, Kurume University School of Medicine, Fukuoka, Japan
    Br J Cancer 88:195-201. 2003
    ..603), but not the other factors, was the independent predictor of the disease death. These results suggest that the %PABS is a novel parameter for predicting the prognosis of patients with advanced prostatic cancer...
  24. doi request reprint A randomized clinical trial of suspension technique for improving early recovery of urinary continence after radical retropubic prostatectomy
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    BJU Int 102:958-63. 2008
    ..To evaluate, in a prospective, single-blind, randomized trial, the safety and efficacy of a suspension technique for improving early recovery of continence after radical retropubic prostatectomy (RRP)...
  25. ncbi request reprint Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Prostate 57:80-92. 2003
    ..To assess the safety and immune response of a peptide-based immunotherapy for patients with hormone-refractory prostate cancer, a phase I clinical trial was conducted...
  26. ncbi request reprint Urodynamic evaluation of a suspension technique for rapid recovery of continence after radical retropubic prostatectomy
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Int J Urol 13:373-8. 2006
    ..We investigated urodynamic findings involved in the rapid recovery of urinary continence after radical retropubic prostatectomy with a suspension technique...
  27. ncbi request reprint Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles
    Elnisr Rashed Mohamed
    Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 34:529-36. 2009
    ..These results suggest that this peptide can be applicable as a cancer vaccine not only for HLA-A24+, but also for HLA-A11+, HLA-A31+ and HLA-A33+ prostate cancer patients...
  28. ncbi request reprint A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients
    Shigeru Yutani
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Oncol Rep 30:1094-100. 2013
    ..Due to the safety profile and the potential clinical efficacy, the conduction of additional clinical trials of PPV for chemotherapy-resistant advanced pancreatic cancer patients is warranted...
  29. ncbi request reprint Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Int J Oncol 29:1555-60. 2006
    ..IgG reactive to the SART3109-118 peptide was frequently detected in the plasma of BC patients. This information could facilitate the development of effective peptide-based immunotherapy for HLA-A24+ BC patients...
  30. ncbi request reprint HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
    Oncol Rep 18:1463-8. 2007
    ..These results indicate that HLA-G-associated immunoregulation can be overcome and that HLA-G peptide-based anti-cancer immunotherapy is feasible...
  31. ncbi request reprint Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles
    Satoko Matsueda
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Clin Cancer Res 11:6933-43. 2005
    ..In this study, we attempted to identify CTL-directed peptide candidates, derived from prostate-related antigens and shared by HLA-A11+, HLA-A31+, and HLA-A33+ prostate cancer patients...
  32. ncbi request reprint New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients
    Akihisa Yao
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Prostate 62:233-42. 2005
    ..Therefore, PTHrP is a promising target in the treatment of metastatic prostate cancer...
  33. ncbi request reprint Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients
    Shigetaka Suekane
    Department of Urology, Kurume University School of Medicine, Fukuoka 830 0011, Japan
    Cancer Sci 98:1965-8. 2007
    ..These results encourage further clinical trials of personalized peptide vaccinations...
  34. ncbi request reprint New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles
    Satoko Matsueda
    Department of Immunology, Karume University School of Medicine, Karume, Fukuoka, Japan
    J Immunother 30:274-81. 2007
    ..This information could expand the chance of a peptide-based cancer vaccine for epithelial cancer patients of many ethnic populations...
  35. ncbi request reprint Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients
    Mamoru Harada
    Department of Immunology, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Oncol Rep 12:601-7. 2004
    ..These results indicate that these PSMA441-450 and PAP112-120 peptides could be promising candidates for peptide-based immunotherapy for HLA-A2(+) prostate cancer...
  36. ncbi request reprint Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer
    Satoko Matsueda
    Department of Immunology, Kurume University School of Medicine, 67 Asahi Machi, Kurume, 830 0011 Fukuoka, Japan
    Cancer Immunol Immunother 53:479-89. 2004
    ....
  37. ncbi request reprint Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles
    Takafumi Minami
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Cancer Immunol Immunother 56:689-98. 2007
    ..These results indicate that these two SART3 peptides could be promising candidates for peptide-based immunotherapy for HLA-A3 supertype(+) prostate cancer patients...
  38. ncbi request reprint Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy
    Shigetaka Suekane
    Department of Urology, Kurume University School of Medicine, Kurume, Japan
    Int J Urol 14:713-8. 2007
    ..We investigated whether the quantitative parameters of systematic sextant biopsies were predictive of either adverse pathological findings or disease recurrence after radical prostatectomy (RP)...
  39. ncbi request reprint A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients
    Satoko Matsueda
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Prostate 60:205-13. 2004
    ..We attempted to identify prostate stem cell antigen (PSCA)-derived peptides immunogenic in HLA-A24+ prostate cancer patients...
  40. ncbi request reprint New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients
    Yukoh Itoh
    Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
    Oncol Rep 18:1231-7. 2007
    ..These results indicate that these EZH2 120-128 and EZH2 165-174 peptides could be promising candidates in peptide-based immunotherapy for HLA-A2+ prostate cancer patients...
  41. ncbi request reprint Identification of target antigens in specific immunotherapy for renal cell carcinoma
    Yoshihiro Komohara
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University, Fukuoka, Japan
    J Urol 177:1157-62. 2007
    ....
  42. doi request reprint Personalized peptide vaccination in patients with refractory non-small cell lung cancer
    Koichi Yoshiyama
    Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Int J Oncol 40:1492-500. 2012
    ..Evaluation of the identified factors before or at an early stage of vaccination could be potentially useful for selecting NSCLC patients who would likely have better prognosis following PPV...
  43. ncbi request reprint Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients
    Mamoru Harada
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Prostate 57:152-9. 2003
    ..We tried to identify prostate-specific antigen (PSA)-derived epitopes immunogenic in HLA-A24+ prostate cancer patients...
  44. doi request reprint An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles
    Yasunobu Terasaki
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Cancer Immunol Immunother 58:1877-85. 2009
    ..These results suggest that this peptide could be widely applicable as a peptide vaccine for HLA-A3 supertype-, HLA-A2-, and -A24-positive cancer patients...
  45. ncbi request reprint Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery
    Shoko Tanaka
    Department of Dermatology, Kurume University of School of Medicine, Fukuoka, Japan
    J Immunother 26:357-66. 2003
    ..These results indicate that peptide vaccination of patients showing evidence of pre-existing peptide-specific CTL precursors can be applied in further clinical trials aimed at the treatment of melanoma and other types of cancer...
  46. ncbi request reprint Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses
    Takashi Mine
    Department of Immunology, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahi Machi, Fukuoka, Kurume 830 0011, Japan
    Clin Cancer Res 10:929-37. 2004
    ..The aim of this study is to find a laboratory marker for overall survival in advanced cancer patients who were vaccinated with peptides based on pre-existing, peptide-specific CTL precursors in the circulation...
  47. doi request reprint Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients
    Yamei Niu
    Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Cancer Sci 100:2167-74. 2009
    ..These results may provide novel information for the development of a peptide-based cancer vaccine for HLA-A26-positive patients...
  48. ncbi request reprint Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients
    Rika Ogata
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Prostate 60:273-81. 2004
    ..Antigens overexpressed in metastatic prostate cancer are appropriate targets in anti-cancer immunotherapy, and one candidate is the polycomb group protein enhancer of zeste homolog 2 (EZH2)...
  49. doi request reprint Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination
    Nobukazu Komatsu
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Cancer 118:3208-21. 2012
    ..Because only a subset of patients show clinical responses to peptide-based cancer vaccination, it is critical to identify biomarkers for selecting patients who would most likely benefit from this treatment...
  50. doi request reprint Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients
    Masayasu Naito
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Prostate 68:1753-62. 2008
    ..To evaluate the immunological responses of personalized peptide vaccination combined with low-dose glucocorticoids for advanced hormone refractory prostate cancer (HRPC) patients (pts)...
  51. ncbi request reprint Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases
    Kazumi Yoshida
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
    Oncol Rep 25:57-62. 2011
    ..Our results suggest that physicians should be on guard for these rare SAEs associated with augmented immune responses...
  52. ncbi request reprint Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Fukuoka, Japan
    Urology 61:993-8. 2003
    ..To investigate the usefulness of bone turnover markers as a modality for monitoring bone metastasis in patients with prostate cancer with bone metastasis...
  53. doi request reprint A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin
    Kazumasa Matsumoto
    Department of Urology, Kitasato University School of Medicine, Japan
    BJU Int 108:831-8. 2011
    ....
  54. doi request reprint Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines
    Tetsuro Sasada
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, Fukuoka, Japan
    Eur J Cancer 46:1514-9. 2010
    ..This article discusses possible ways to overcome the hurdles of randomised clinical trials of therapeutic cancer vaccines based on a review of recently conducted clinical trials...
  55. ncbi request reprint Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients
    Kazuhiko Kobayashi
    Department of Immunology and Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830 0011, Japan
    Cancer Sci 94:622-7. 2003
    ..These results demonstrate that the PSMA 624-632 peptide could be an appropriate molecule for use in specific immunotherapy of HLA-A24(+) patients with prostate cancer...
  56. ncbi request reprint Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Japan
    J Urol 170:459-63. 2003
    ..We evaluated secondary cancers in the prostate in relation to predictions of pathological stage and prognosis...
  57. doi request reprint Next-generation peptide vaccines for advanced cancer
    Akira Yamada
    Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan
    Cancer Sci 104:15-21. 2013
    ....
  58. doi request reprint Recent advances in cancer vaccines: an overview
    Kyogo Itoh
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Jpn J Clin Oncol 39:73-80. 2009
    ....
  59. ncbi request reprint Target molecules in specific immunotherapy against prostate cancer
    Mamoru Harada
    Department of Immunology, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Int J Clin Oncol 8:193-9. 2003
    ....
  60. ncbi request reprint Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: the robustness of prostate cancer
    Shigenori Homma
    Department of Immunology, Kurume University School of Medicine, Fukuoka 830 0011, Japan
    Oncol Rep 18:343-6. 2007
    ....
  61. pmc Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer
    Tetsuro Sasada
    Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
    Hum Vaccin Immunother 8:1309-13. 2012
    ..Further randomized phase III trials would be recommended to prove clinical benefits of PPV...
  62. ncbi request reprint Bilateral neurovascular bundles sparing prostatectomy preserves sexual function in patients with localized prostate cancer
    Makoto Nakiri
    Department of Urology, Kurume University School of Medicine, Kurume 830 0011, Japan
    Kurume Med J 55:63-9. 2008
    ..0001). In order to maintain sexual function following radical retropubic prostatectomy, the bilateral neurovascular bundles should be preserved, as far as practicable...
  63. ncbi request reprint [Personalized peptide vaccination]
    Kyogo Itoh
    Department of Immunology and Immunotherapy, Kurume University School of Medicine
    Nihon Rinsho 70:2118-23. 2012
    ..6 months, resulting in the initiation of randomized phase III clinical trial. A randomized phase III trial is essential to prove clinical benefits of PPV...
  64. ncbi request reprint Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case
    Kousuke Ueda
    Department of Urology, Kurume University School of Medicine, Kurume University, Kurume, Japan
    Kurume Med J 58:95-8. 2011
    ..Our experience with the present case suggests that targeted therapy in the neoadjuvant setting may have a variety of potential applications. Further investigations should be encouraged...
  65. ncbi request reprint Solitary fibrous tumor arising from the prostatic capsule
    Masanori Noguchi
    Department of Urology, Kurume University School of Medicine, Fukuoka, Japan
    J Urol 168:1490-1. 2002
  66. ncbi request reprint Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient
    Mamoru Harada
    Department of Immunology, Kurume University of School of Medicine, Fukuoka 830 0011, Japan
    J Immunother 28:368-75. 2005
    ..These findings indicate that vaccination with CTL-directed peptides, including a PSA-derived peptide, was able to elicit and spread humoral and TH1-type immune responses to the PSA protein...
  67. ncbi request reprint Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer
    M Noguchi
    Department of Urology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011 Japan
    J Urol 166:1106-10. 2001
    ..CONCLUSIONS: Measuring serum ICTP may be useful for detecting bone metastasis and prostate cancer progression, and may augment PSA and bone scan monitoring of metastatic bone activity...
  68. ncbi request reprint Separation and identification of the regioisomers of verdoheme by reversed-phase ion-pair high-performance liquid chromatography, and characterization of their complexes with heme oxygenase
    H Sakamoto
    Department of Medical Biochemistry, Kurume University School of Medicine, Japan
    J Inorg Biochem 82:113-21. 2000
    ....
  69. ncbi request reprint Expression of APOBEC3G in kidney cells
    Y Komohara
    Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Tissue Antigens 69:95-8. 2007
    ..These results may provide new insight into the role of APOBEC3G in host defense against viral infection and cancer...
  70. ncbi request reprint Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment
    J Yahara
    Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    BJU Int 92:379-83; discussion 383-4. 2003
    ..To assess the clinical usefulness of quantifying the extent of disease on bone scans in monitoring treatment response in patients with advanced prostate cancer, using computer-assisted image analysis...
  71. ncbi request reprint Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide
    Y Inoue
    Pharmacology Division, Department of Urology, Transplantation Unit, National Cancer Center, Chuo Ku, Tokyo, Japan
    J Urol 166:1508-13. 2001
    ..We investigated whether HLA-A2402 binding prostatic acid phosphatase derived peptides induce HLA-A2402 restricted, tumor specific cytotoxic T lymphocytes from the peripheral blood mononuclear cells of patients with prostate cancer...
  72. ncbi request reprint Necessity of repeat biopsies in men for suspected prostate cancer
    M Noguchi
    Department of Urology, Kurume University School of Medicine, Japan
    Int J Urol 6:7-12. 1999
    ..The indications for repeat prostate needle biopsy in men whose initial biopsy results revealed no evidence of cancer are not defined...
  73. pmc Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients
    A Yao
    Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan
    Br J Cancer 91:287-96. 2004
    ..These results indicate that the PTHrP could be a promising target molecule for specific immunotherapy of HLA-A24(+) prostate cancer patients with metastases...
  74. ncbi request reprint TAC-101, a novel retinobenzoic-acid derivative, enhances gap junctional intercellular communication among renal epithelial cells treated with renal carcinogens
    T Miyaguchi
    Department of Urology, Nagasaki University School of Medicine, Japan
    Anticancer Res 21:4025-30. 2001
    ..Consequently, TAC-101 prevented the disruption of GJIC in MDCK cells. These data suggested that TAC-101 enhanced GJIC by up-regulating Cx43 expression and that TAC-101 might be useful for the prevention of renal cell carcinoma...
  75. ncbi request reprint Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma
    Y Miyata
    Department of Urology, Nagasaki University School of Medicine, Sakamoto, Nagasaki City, Japan
    Urology 58:161-4. 2001
    ....
  76. pmc Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles
    M Naito
    Department of Immunology, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    Br J Cancer 97:1648-54. 2007
    ..This information could facilitate the development of peptide-based anti-cancer vaccine for patients with alleles other than HLA-A2 and -A24...
  77. ncbi request reprint [Acquired tumor "robustness" in the case of prostate cancer]
    Shigenori Homma
    Dept of Immunology, Kurume University School of Medicine
    Gan To Kagaku Ryoho 33:1748-50. 2006
    ....